User:Brim/stuff

Stuff to add:

• Chamberlain prodedure
• ACOSOG Z0050 (PET for Lung ca)
• cyrotherapy - Jewel THompson effect, Argon
• ICRU publications 38/50/62
• Prostate MRI: T2 best for visualizing prostate gland, T1 for showing post-bx hemorrhage, can use T1 or T2 for LN
• American Urologic Association (AUA) stage for prostate
• [training.seer.cancer.gov/ss]
• MRI: Choline/Creatinine ratio versus Citrate. In cancer, citrate is lowered, and choline/creat is increased
• MRI: diffusion coefficient decreased in tumor
• Prostate: T3, include all SV in PTV
• Prostate: RTOG P-0126, 79.2 Gy vs 70.2, Int Risk
• Prostate: ext/int iliac LN. common iliac uncommon. presarcal uncommon.
• Look up: Radiol 211: 815-828, 1991 - cross sectional nodal anatomy
• ASTRO 2004: LN relationship to vessels (prostate)
• Prostate "standard" pelvic field: up to L4/L5
• Treatment planning: EUD (equivalent uniform dose), TCP/NTCP (biological cost function), Lyman - sigmoid curve
• Treatment planning: score, uncomplicated tumor control S=T(1-P1)*(1-P2)
• Langer et al, Kallman et al.
• EUD: Niemierco and Mohan
• EUD=[volume*dose^a]^(1/a)... where a=exponent. if a>>0, EUD trends toward max dose. if a<<0 trends toward min dose
• inverse planning algorithms:
  • exhausive search, 1960s
  • simulated annealing (Kirkpatrick 1983, Gemen 1984, Aarts 1985, Webb 1989)
  • filtered backprojection - based on inverse CT technique, Fourier transform. but often gives negative doses which aren't possible
  • L.Xing, Med PHys 25, 1845-49 - iterative method
  • genetic algorithms
• GIST - KIT tyrosine kinase receptor, binds growth factor
• SARCOMA:
  • Rosenberg 1982, NCI - amp vs surg/xrt
  • Pisters, MSKCC, JCO 1996 - surg vs surg/xrt
  • Yang, NCI, 1998
  • O'Sullivan NCIC, Lancet 2002 - pre-op vs post-op
  • LR/OS/Regional/Distant control - same for pre/post-op (already metastatic?). post-op has worse grade 3/4 fibrosis (36% vs 23% for preop)
  • fractures 10% at 60-66 Gy (postop) vs 2% for preop 50 Gy
  • preop more wound complications
  • tumor cells >1cm from tumor in 1/3 of cases -- need for large margins
• HODGKIN LYMPHOMA (correct name)
  • Rye 1966, WHO 2001 (added lymphocyte rich classical HL)
  • use ABVD chemo + IF-XRT 30-36 Gy
  • early stage: extended field + ABVD - high risk of 2nd malignancy, but good cause-specific survival (overall survival is less)

    Milan 1990-1996, EFRT v IFRT (30-36 Gy) x 4 cycles chemo

    EORTC H8F

    Engent JCo 21: 3601, 2003

    new std of care is short course chemo + IF-RT

• MALT LYMPHOMA (stomach) - treated like low grade
  • stomach 18 Gy AP/PA, boost obliques to 36 Gy off kidneys
  • new disease - described in 1980s
  • 1/3 have diffuse disease (Stage III-IV)
  • if treat H.pylori may regress. response can take 6 months. assay C-14 urea breath test to follow response, not antibodies
  • Tsang, PMH, JCO 2003, 21:4157
  • 100% control w XRT

• BURKITT'S LYMHOMA
  • "starry sky"
  • BCL-2 negative usually
• CNS: RTOG 95-08
• defn of "conformity index" (by Paddick)
• GK: trigeminal neuralgia, 75 Gy
• RPA classification for GBM, Curran 1993 - I to VI
• RPA for mets
• RTOG 93-05 - GBM... RT+BCNU vs GK then RT+BCNU
• RTOG 80-07: neutrons for GBM

NEED TO FIX:

• At RTOG page, 78-03 and 76-15 have same PMID. Which is correct? RTOG 76-15 need ref.

Miscellaneous info

Wikibook stats: http://wikistics.falsikon.de/latest/wikibooks/en (found here)